Patent 10828345
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Active provider: Google · gemini-2.5-flash
PTAB activity (1)
AIA trial proceedings — IPR, PGR, CBM — filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced directly from the PTAB Trial API.
- IPR2025-01269IPRfiled Jul 14, 2025vs. Fresenius Kabi SwissBiosim, GmbH et al.Institution Denied
Cached for 24 hours. Status strings are sourced verbatim from the PTAB API; the colored badge is our heuristic classification.
Cases on file (3)
Group view →Specific litigation cases in our database that name US patent 10828345. The free-form analysis below may also discuss cases beyond this list.
- IPR2025-01269Patent Trial and Appeal Board (PTAB)Not Instituted - Merits
Defendants: Regeneron Pharmaceuticals Inc.
- 1:24-cv-00085West Virginia Northern District Court
Defendants: Mylan Pharmaceuticals Inc.
- 3:24-cv-08760New Jersey District Court
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
US Patent 10,828,345 is involved in several litigation cases, primarily concerning its relationship to Aflibercept and methods for treating angiogenic eye disorders. Regeneron Pharmaceuticals Inc. is the current assignee of the patent.
Known litigation involving US patent 10,828,345 includes:
I. Patent Trial and Appeal Board (PTAB) Cases:
Case: IPR2025-01269
- Plaintiff(s): Petitioner (Unified Patents)
- Defendant(s): Patent Owner (Regeneron Pharmaceuticals Inc.)
- Jurisdiction: Patent Trial and Appeal Board (PTAB)
- Case Number: IPR2025-01269
- Filing Date: Not explicitly provided in the available snippets for the IPR itself, but it is a 2025 filing.
- Outcome/Current Status: Not Instituted - Merits
Case: PGR2021-00035
- Plaintiff(s): Petitioner (Unified Patents)
- Defendant(s): Patent Owner (Regeneron Pharmaceuticals Inc.)
- Jurisdiction: Patent Trial and Appeal Board (PTAB)
- Case Number: PGR2021-00035
- Filing Date: Not explicitly provided in the available snippets for the PGR itself, but it is a 2021 filing.
- Outcome/Current Status: Procedural Termination
II. U.S. District Court Cases:
US patent 10,828,345 B2 is identified as one of the patents claiming priority within the context of "In re Aflibercept Patent Litigation MDL No. 3103". In this context, Regeneron Pharmaceuticals, Inc. is the Patent Owner.
Jurisdiction: West Virginia Northern District Court
- Plaintiff(s): Regeneron Pharmaceuticals Inc. (Inferred as patent owner asserting infringement based on related litigation in MDL 3103 involving Regeneron v. Mylan)
- Defendant(s): Mylan Pharmaceuticals Inc. (Inferred as a defendant in related Aflibercept litigation)
- Case Numbers & Filing Years:
- 1:24-cv-00085 (Filed in 2024)
- 1:24-cv-00053 (Filed in 2024)
- 1:24-cv-00039 (Filed in 2024)
- 1:23-cv-00089 (Filed in 2023)
- Outcome/Current Status: Not specified in the available snippets.
Jurisdiction: New Jersey District Court
- Plaintiff(s): Regeneron Pharmaceuticals Inc. (Inferred as patent owner asserting infringement based on related litigation in MDL 3103)
- Defendant(s): Not explicitly named in the available snippets.
- Case Number: 3:24-cv-08760
- Filing Date: Filed in 2024
- Outcome/Current Status: Not specified in the available snippets.
Jurisdiction: California Central District Court
- Plaintiff(s): Regeneron Pharmaceuticals Inc. (Inferred as patent owner asserting infringement based on related litigation in MDL 3103)
- Defendant(s): Not explicitly named in the available snippets.
- Case Number: 2:24-cv-00264
- Filing Date: Filed in 2024
- Outcome/Current Status: Not specified in the available snippets.
Generated 5/20/2026, 12:47:29 AM